184 related articles for article (PubMed ID: 23014894)
1. Phenprocoumon and acenocoumarol treatment in paediatric patients.
Spoor N; Smiers FJ; van der Meer FJ; Hutten BA; van Ommen CH
Thromb Haemost; 2012 Dec; 108(6):1238-41. PubMed ID: 23014894
[No Abstract] [Full Text] [Related]
2. The relationship between maintenance dosages of three vitamin K antagonists: acenocoumarol, warfarin and phenprocoumon.
van Leeuwen Y; Rosendaal FR; van der Meer FJ
Thromb Res; 2008; 123(2):225-30. PubMed ID: 18407321
[TBL] [Abstract][Full Text] [Related]
3. Subtherapeutic oral anticoagulant therapy: frequency and risk factors.
Rombouts EK; Rosendaal FR; van der Meer FJ
Thromb Haemost; 2009 Mar; 101(3):552-6. PubMed ID: 19277419
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort.
Maagdenberg H; Bierings MB; van Ommen CH; van der Meer FJM; Appel IM; Tamminga RYJ; de Boer A; Maitland-van der Zee AH
J Thromb Haemost; 2018 Jan; 16(1):116-124. PubMed ID: 29108090
[TBL] [Abstract][Full Text] [Related]
5. [Oral anticoagulation with vitamin K antagonists].
Alberio L
Ther Umsch; 2003 Jan; 60(1):5-9. PubMed ID: 12638470
[TBL] [Abstract][Full Text] [Related]
6. Understanding low INR in clinical practice.
Hylek EM; Rose AJ
Thromb Haemost; 2009 Mar; 101(3):417-8. PubMed ID: 19277399
[No Abstract] [Full Text] [Related]
7. Invasive procedures in the outpatient setting: managing the short-acting acenocoumarol and the long-acting phenprocoumon.
van Geest-Daalderop JH; Hutten BA; Péquériaux NC; de Vries-Goldschmeding HJ; Räkers E; Levi M
Thromb Haemost; 2007 Oct; 98(4):747-55. PubMed ID: 17938797
[TBL] [Abstract][Full Text] [Related]
8. Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.
Zhang Y; de Boer A; Verhoef TI; van der Meer FJ; Le Cessie S; Maitland-van der Zee AH; ;
Thromb Res; 2015 Jul; 136(1):94-100. PubMed ID: 25971661
[TBL] [Abstract][Full Text] [Related]
9. Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: A cohort study.
van Miert JHA; Veeger NJGM; Ten Cate-Hoek AJ; Piersma-Wichers M; Meijer K
PLoS One; 2020; 15(7):e0235639. PubMed ID: 32649714
[TBL] [Abstract][Full Text] [Related]
10. Variability of INR in patients on stable long-term treatment with phenprocoumon and acenocoumarol and implications for analytical quality requirements.
van Geest-Daalderop JH; Péquériaux NC; van den Besselaar AM
Thromb Haemost; 2009 Sep; 102(3):588-92. PubMed ID: 19718481
[TBL] [Abstract][Full Text] [Related]
11. [Partial resistance to acenocoumarol and phenprocoumon caused by enzyme polymorphism].
Wilms EB; Veldkamp RF; van Meegen E; Touw DJ
Ned Tijdschr Geneeskd; 2006 Sep; 150(38):2095-8. PubMed ID: 17036862
[TBL] [Abstract][Full Text] [Related]
12. Optimization of vitamin K antagonist drug dose finding by replacement of the international normalized ratio by a bidirectional factor: validation of a new algorithm.
Beinema MJ; van der Meer FJ; Brouwers JR; Rosendaal FR
J Thromb Haemost; 2016 Mar; 14(3):479-84. PubMed ID: 26712475
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon.
Gadisseur AP; van der Meer FJ; Adriaansen HJ; Fihn SD; Rosendaal FR
Br J Haematol; 2002 Jun; 117(4):940-6. PubMed ID: 12060134
[TBL] [Abstract][Full Text] [Related]
14. Overanticoagulation associated with combined use of lactulose and acenocoumarol or phenprocoumon.
Visser LE; Penning-van Beest FJ; Wilson JH; Vulto AG; Kasbergen AA; De Smet PA; Hofman A; Stricker BH
Br J Clin Pharmacol; 2004 Apr; 57(4):522-4. PubMed ID: 15025752
[TBL] [Abstract][Full Text] [Related]
15. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants.
Visser LE; Penning-van Bees FJ; Kasbergen AA; De Smet PA; Vulto AG; Hofman A; Stricker BH
Thromb Haemost; 2002 Nov; 88(5):705-10. PubMed ID: 12428081
[TBL] [Abstract][Full Text] [Related]
16. INR variability in anticoagulation with acenocoumarol: is it useful for identifying patients at risk of bleeding and thrombosis?
Casais P; Sánchez Luceros A; Meschengieser S; Bermejo E; Lazzari MA
Haematologica; 1999 Aug; 84(8):753-4. PubMed ID: 10457416
[No Abstract] [Full Text] [Related]
17. Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon.
Becker ML; Franken WP; Karapinar F; Verzijl-Zeegers R; Schalekamp T; van der Hoeven RT
Eur J Clin Pharmacol; 2015 Dec; 71(12):1461-5. PubMed ID: 26400679
[TBL] [Abstract][Full Text] [Related]
18. Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists.
van Rein N; Lijfering WM; Bos MH; Herruer MH; Vermaas HW; van der Meer FJ; Reitsma PH
PLoS One; 2016; 11(12):e0164485. PubMed ID: 27935941
[TBL] [Abstract][Full Text] [Related]
19. Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists.
de Koning MLY; Fischer K; de Laat B; Huisman A; Ninivaggi M; Schutgens REG
J Thromb Haemost; 2017 May; 15(5):868-875. PubMed ID: 28296129
[TBL] [Abstract][Full Text] [Related]
20. Invited commentary.
Hiratzka LF
Ann Thorac Surg; 2010 Nov; 90(5):1521-2. PubMed ID: 20971253
[No Abstract] [Full Text] [Related]
[Next] [New Search]
